Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21.

Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, Muise ES, Zhang KX, Arazi A, Keras G, Li ZJ, Qu Y, Gurish MF, Petri M, Buyon JP, Putterman C, Wofsy D, James JA, Guthridge JM, Diamond B, Anolik JH, Mackey MF, Alves SE, Nigrovic PA, Costenbader KH, Brenner MB, Lederer JA, Rao DA; Accelerating Medicines Partnership (AMP) RA/SLE Network.

JCI Insight. 2019 Oct 17;4(20). pii: 130062. doi: 10.1172/jci.insight.130062.

2.

Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme.

Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, Fleuranceau-Morel P.

Rheumatol Adv Pract. 2019 Aug 6;3(2):rkz021. doi: 10.1093/rap/rkz021. eCollection 2019.

3.

The Accelerating Medicines Partnership - Organizational Structure and Preliminary Data from the Phase 1 Studies of Lupus Nephritis.

Hoover P, Der E, Berthier CC, Arazi A, Lederer JA, James JA, Buyon J, Petri M, Belmont HM, Izmirly P, Wofsy D, Hacohen N, Diamond B, Putterman C, Davidson A.

Arthritis Care Res (Hoboken). 2019 Sep 9. doi: 10.1002/acr.24066. [Epub ahead of print] Review.

PMID:
31502417
4.

The Validity of Scores from the New MCAT Exam in Predicting Student Performance: Results from a Multisite Study.

Busche K, Elks ML, Hanson JT, Jackson-Williams L, Manuel RS, Parsons WL, Wofsy D, Yuan K.

Acad Med. 2019 Aug 13. doi: 10.1097/ACM.0000000000002942. [Epub ahead of print]

PMID:
31425189
5.

Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis.

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network.

Nat Immunol. 2019 Oct;20(10):1404. doi: 10.1038/s41590-019-0473-3.

PMID:
31409923
6.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
7.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

PMID:
31383717
8.

The immune cell landscape in kidneys of patients with lupus nephritis.

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network.

Nat Immunol. 2019 Jul;20(7):902-914. doi: 10.1038/s41590-019-0398-x. Epub 2019 Jun 17. Erratum in: Nat Immunol. 2019 Aug 13;:.

PMID:
31209404
9.

Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus.

Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Ann Rheum Dis. 2019 May;78(5):634-640. doi: 10.1136/annrheumdis-2018-214685. Epub 2019 Jan 28.

10.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2019 Jul;46(7):721-726. doi: 10.3899/jrheum.180478. Epub 2018 Dec 15.

PMID:
30554156
11.

Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus.

Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD; Autoimmunity Centers of Excellence.

Arthritis Rheumatol. 2019 Mar;71(3):431-440. doi: 10.1002/art.40737. Epub 2019 Jan 24.

PMID:
30277008
12.

Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis.

Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, Wofsy D, Hebert L.

Kidney Int Rep. 2018 Apr 27;3(5):1057-1063. doi: 10.1016/j.ekir.2018.04.010. eCollection 2018 Sep.

13.

Do Admissions Multiple Mini-Interview and Traditional Interview Scores Predict Subsequent Academic Performance? A Study of Five California Medical Schools.

Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Tancredi DJ, Sousa FJ, Franks P.

Acad Med. 2019 Mar;94(3):388-395. doi: 10.1097/ACM.0000000000002440.

PMID:
30188370
14.

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.

Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS.

Ann Rheum Dis. 2018 Jun;77(6):883-889. doi: 10.1136/annrheumdis-2018-213032. Epub 2018 Mar 21.

15.

Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools?

Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P.

Acad Med. 2018 Aug;93(8):1227-1233. doi: 10.1097/ACM.0000000000002223.

16.

Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis.

Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D.

Lupus Sci Med. 2017 Aug 31;4(1):e000229. doi: 10.1136/lupus-2017-000229. eCollection 2017.

17.

Reliability of Multiple Mini-Interviews and traditional interviews within and between institutions: a study of five California medical schools.

Jerant A, Henderson MC, Griffin E, Rainwater JA, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P.

BMC Med Educ. 2017 Nov 6;17(1):190. doi: 10.1186/s12909-017-1030-0.

18.

Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study.

Henderson MC, Kelly CJ, Griffin E, Hall TR, Jerant A, Peterson EM, Rainwater JA, Sousa FJ, Wofsy D, Franks P.

Acad Med. 2018 Jul;93(7):1029-1034. doi: 10.1097/ACM.0000000000002041.

PMID:
29095170
19.

Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.

Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):571-581. doi: 10.1002/acr.23317. Epub 2018 Feb 22. Review.

20.

Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.

Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D.

Arthritis Rheumatol. 2017 Jan;69(1):122-130. doi: 10.1002/art.39809. Epub 2016 Dec 2.

21.

In memoriam: Ephraim P. Engleman, MD, 1911-2015.

Wofsy D.

Arthritis Rheumatol. 2015 Nov;67(11):2795-6. doi: 10.1002/art.39440. No abstract available.

22.

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome.

Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D.

Lupus Sci Med. 2015 May 20;2(1):e000089. doi: 10.1136/lupus-2015-000089. eCollection 2015.

23.

Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America.

Wofsy D, Diamond B, Houssiau FA.

Arthritis Rheumatol. 2015 May;67(5):1144-6. doi: 10.1002/art.39067. No abstract available.

24.

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D.

Ann Rheum Dis. 2015 Nov;74(11):2006-15. doi: 10.1136/annrheumdis-2013-205067. Epub 2014 Jun 20. Erratum in: Ann Rheum Dis. 2016 May;75(5):946.

25.

Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials.

Wofsy D, Hillson JL, Diamond B.

Arthritis Rheum. 2013 Jun;65(6):1586-91. doi: 10.1002/art.37940.

26.

Recent progress in conventional and biologic therapy for systemic lupus erythematosus.

Wofsy D.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii66-8. doi: 10.1136/annrheumdis-2012-202204. Epub 2012 Dec 19. Review.

PMID:
23253930
27.

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.

Wofsy D, Hillson JL, Diamond B.

Arthritis Rheum. 2012 Nov;64(11):3660-5. doi: 10.1002/art.34624.

28.

Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group.

N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460.

29.

A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis.

Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE.

J Rheumatol. 2011 May;38(5):846-54. doi: 10.3899/jrheum.100602. Epub 2011 Feb 1.

PMID:
21285160
30.

Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.

Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D.

Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7. doi: 10.1002/acr.20397. Epub 2010 Nov 15.

31.

Plagiarism on personal statements: a disturbing symptom of a broader trend.

Papadakis MA, Wofsy D.

Ann Intern Med. 2010 Jul 20;153(2):128-9. doi: 10.7326/0003-4819-153-2-201007200-00010. No abstract available.

PMID:
20643994
32.

Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through?

Dall'Era M, Wofsy D.

Nat Rev Rheumatol. 2010 Mar;6(3):124-5. doi: 10.1038/nrrheum.2010.20. No abstract available.

PMID:
20197774
33.

Biologic therapy for systemic lupus erythematosus.

Dall'Era M, Wofsy D.

Discov Med. 2010 Jan;9(44):20-3. Review.

34.

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.

Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA; ALMS Group.

Arthritis Rheum. 2010 Jan;62(1):211-21. doi: 10.1002/art.25052. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

35.

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.

Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N.

Rheumatology (Oxford). 2010 Jan;49(1):128-40. doi: 10.1093/rheumatology/kep346. Epub 2009 Nov 20.

36.

Regulatory T cells as therapeutic targets in rheumatoid arthritis.

Esensten JH, Wofsy D, Bluestone JA.

Nat Rev Rheumatol. 2009 Oct;5(10):560-5. doi: 10.1038/nrrheum.2009.183. Review.

37.

Systemic lupus erythematosus clinical trials-an interim analysis.

Dall'Era M, Wofsy D.

Nat Rev Rheumatol. 2009 Jun;5(6):348-51. doi: 10.1038/nrrheum.2009.79. Review.

PMID:
19491915
38.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group.

J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15.

39.

Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest.

Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D.

JAMA. 2009 Apr 1;301(13):1367-72. doi: 10.1001/jama.2009.407.

PMID:
19336712
40.

A quality indicator set for systemic lupus erythematosus.

Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E; Systemic Lupus Erythematosus Quality Indicators Project Expert Panels.

Arthritis Rheum. 2009 Mar 15;61(3):370-7. doi: 10.1002/art.24356.

41.

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D.

Arthritis Rheum. 2007 Dec;56(12):4142-50.

42.

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N.

Lupus. 2007;16(12):972-80.

PMID:
18042591
43.

Clinical trial design in systemic lupus erythematosus.

Dall'Era M, Wofsy D.

Curr Opin Rheumatol. 2006 Sep;18(5):476-80. Review.

PMID:
16896285
44.

Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases.

Daikh DI, Gillis J, Wofsy D.

Arthritis Rheum. 2006 Apr 15;55(2):322-4. No abstract available.

45.

Block and tackle: CTLA4Ig takes on lupus.

Davidson A, Diamond B, Wofsy D, Daikh D.

Lupus. 2005;14(3):197-203. Review.

PMID:
15807196
46.

Living in a different world.

Wofsy D.

Arthritis Rheum. 2005 Feb;52(2):395-401. No abstract available.

47.

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group.

Arthritis Rheum. 2002 Dec;46(12):3251-8.

48.

Treatment of autoimmune diseases by inhibition of T-cell costimulation.

Wofsy D, Daikh DI.

Mod Rheumatol. 2002 Mar;12(1):1-4. doi: 10.3109/s101650200000.

PMID:
24383824
49.

The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic.

Diamond B, Bluestone J, Wofsy D.

Arthritis Rheum. 2001 Aug;44(8):1730-5. Review.

50.

Treatment of autoimmunity by inhibition of T cell costimulation.

Daikh DI, Wofsy D.

Adv Exp Med Biol. 2001;490:113-7. Review. No abstract available.

PMID:
11505969

Supplemental Content

Support Center